XML 15 R5.htm IDEA: XBRL DOCUMENT v3.21.2
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
shares in Thousands, $ in Thousands
Total
Common Stock
Additional Paid-In Capital
Accumulated Other Comprehensive Loss
Accumulated Deficit
Beginning Balance at Dec. 31, 2019 $ 4,836 $ 2 $ 243,281   $ (238,447)
Beginning Balance, shares at Dec. 31, 2019   2,179      
Issuance of common stock for release of awards (1)   (1)    
Issuance of common stock for release of awards, shares   20      
Exercise of pre-funded warrants 2   2    
Exercise of pre-funded warrants, shares   116      
Stock-based compensation 68   68    
Net loss (1,405)       (1,405)
Ending Balance at Mar. 31, 2020 3,500 $ 2 243,350   (239,852)
Ending Balance, shares at Mar. 31, 2020   2,315      
Beginning Balance at Dec. 31, 2019 4,836 $ 2 243,281   (238,447)
Beginning Balance, shares at Dec. 31, 2019   2,179      
Deemed dividend for warrant exercise price adjustment 392        
Net loss (2,044)        
Ending Balance at Jun. 30, 2020 4,546 $ 3 245,426   (240,883)
Ending Balance, shares at Jun. 30, 2020   3,534      
Beginning Balance at Mar. 31, 2020 3,500 $ 2 243,350   (239,852)
Beginning Balance, shares at Mar. 31, 2020   2,315      
Issuance of common stock for release of awards, shares   1      
Sale of common stock, net of placement costs 1,619 $ 1 1,618    
Sale of common stock, net of placement costs,shares   1,218      
Deemed dividend for warrant exercise price adjustment 392   392   (392)
Stock-based compensation 66   66    
Net loss (639)       (639)
Ending Balance at Jun. 30, 2020 4,546 $ 3 245,426   (240,883)
Ending Balance, shares at Jun. 30, 2020   3,534      
Beginning Balance at Dec. 31, 2020 $ 2,932 $ 3 245,548   (242,619)
Beginning Balance, shares at Dec. 31, 2020 3,554 3,554      
Issuance of common stock under stock plan, net $ (2)   (2)    
Issuance of common stock under stock plan, net, shares   16      
Exercise of warrants 2,478 $ 1 2,477    
Exercise of warrants, shares   1,033      
Issuance of common stock for payment of accrued interest 140   140    
Issuance of common stock for payment of accrued interest,shares   43      
Sale of common stock, net of placement costs 6,817 $ 2 6,815    
Sale of common stock, net of placement costs,shares   1,488      
Stock-based compensation 68   68    
Unrealized loss on available-for-sale investments (1)     $ (1)  
Net loss (1,369)       (1,369)
Ending Balance at Mar. 31, 2021 11,063 $ 6 255,046 (1) (243,988)
Ending Balance, shares at Mar. 31, 2021   6,134      
Issuance of common stock under stock plan, net 2   2    
Beginning Balance at Dec. 31, 2020 $ 2,932 $ 3 245,548   (242,619)
Beginning Balance, shares at Dec. 31, 2020 3,554 3,554      
Unrealized loss on available-for-sale investments $ (4)        
Net loss (2,574)        
Ending Balance at Jun. 30, 2021 $ 23,617 $ 8 268,806 (4) (245,193)
Ending Balance, shares at Jun. 30, 2021 8,660 8,660      
Beginning Balance at Mar. 31, 2021 $ 11,063 $ 6 255,046 (1) (243,988)
Beginning Balance, shares at Mar. 31, 2021   6,134      
Issuance of common stock under stock plan, net, shares   2      
Exercise of warrants 1,696 $ 1 1,695    
Exercise of warrants, shares   706      
Sale of common stock, net of placement costs 11,969 $ 1 11,968    
Sale of common stock, net of placement costs,shares   1,818      
Stock-based compensation 97   97    
Unrealized loss on available-for-sale investments (3)     (3)  
Net loss (1,205)       (1,205)
Ending Balance at Jun. 30, 2021 $ 23,617 $ 8 $ 268,806 $ (4) $ (245,193)
Ending Balance, shares at Jun. 30, 2021 8,660 8,660